Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan

References

• Kawasaki R, Wang JJ, Ji GJ, et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology 2008;115:1376-81
   PubMed Web of Science ®Google Scholar
• Nakata I, Yamashiro K, Nakanishi H, et al. Prevalence and characteristics of age-related macular degeneration in the Japanese population: the Nagahama study. Am J Ophthalmol 2013;156:1002-9
   PubMed Web of Science ®Google Scholar
• Yamada M, Hiratsuka Y, Roberts CB, et al. Prevalence of visual impairment in the adult Japanese population by cause and severity and future projections. Ophthalmic Epidemiol 2010;17:50-7
   PubMed Web of Science ®Google Scholar
• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106-e116
   PubMed Web of Science ®Google Scholar
• Kulkarni AD, Kuppermann BD. Wet age-related macular degeneration. Adv Drug Deliv Rev 2005;57:1994-2009
   PubMed Web of Science ®Google Scholar
• Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs 2008;68:1029-36
   PubMed Web of Science ®Google Scholar
• Kovach JL, Schwartz SG, Flynn HW Jr, et al. Anti-VEGF treatment strategies for wet AMD. J Ophthalmol 2012;2012:786870
   PubMed Web of Science ®Google Scholar
• Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51
   PubMed Web of Science ®Google Scholar
• Ablonczy Z, Dahrouj M, Marneros AG. Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels. FASEB J 2014;28:2369-79
   PubMed Web of Science ®Google Scholar
• Ho QT, Kuo CJ. Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 2007;39:1349-57
   PubMed Web of Science ®Google Scholar
• Heier JS, VIEW 1 Investigators, VIEW 2 Investigators. 96 weeks results from the VIEW 1 and VIEW 2 studies: intravitreal aflibercept injection versus ranibizumab for neovascular AMD shows sustained improvements in visual acuity. Presented at Association for Research in Vison and Ophthalmology (ARVO) Fort Lauderdale, FL; 2012
   Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193-201
   PubMed Web of Science ®Google Scholar
• Ogura Y, Terasaki H, Gomi F, et al. Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Ophthalmol 2015;99:92-7
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Macular degeneration (wet age-related) – aflibercept (TA294). Lindon, UK. http://guidance.nice.org.uk/TA294. Accessed October 14, 2016
   Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford, UK: Oxford University Press, 2005
   Google Scholar
• Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc 2008;6:12
   PubMedGoogle Scholar
• Colquitt JL, Jones J, Tan SC, et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2008;12:iii-201
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
   PubMed Web of Science ®Google Scholar
• Schmier JK, Hulme-Lowe CK. Cost-effectiveness models in age-related macular degeneration: issues and challenges. Pharmacoeconomics 2016;34:259-72
   PubMed Web of Science ®Google Scholar
• Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, et al. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration. Clin Ther 2008;30:2436-51
   PubMed Web of Science ®Google Scholar
• Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol 2004;88:982-7
   PubMed Web of Science ®Google Scholar
• Meads C, Salas C, Roberts T, et al. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2003;7:v-98
   PubMedGoogle Scholar
• Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther 2007;29:2096-106
   PubMed Web of Science ®Google Scholar
• Javitt JC, Zlateva GP, Earnshaw SR, et al. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health 2008;11:563-74
   PubMed Web of Science ®Google Scholar
• Neubauer AS, Holz FG, Schrader W, et al. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration]. Klin Monbl Augenheilkd 2007;224:727-32
   PubMed Web of Science ®Google Scholar
• Japanese Government Ministry of Health Labour and Welfare. The 21st Life Tables. Statistics and Information- Department Minister's Secretariat. Tokyo, Japan. 2010 http://www.mhlw.go.jp/english/database/db-hw/lifetb21th/dl/data.pdf. Accessed October 14, 2016
   Google Scholar
• Guideline for economic evaluation of healthcare technologies in Japan. Tokyo: Research group on economic evaluation for Japanese public medical benefits Website, 2013. http://hta.umin.jp/guideline_e.pdf. Accessed October 14, 2016
   Google Scholar
• Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422-37
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Igarashi A, Fukuda T, et al. WTP for a QALY and health states: more money for severer health states? Cost Eff Resour Alloc 2013;11:22
   PubMedGoogle Scholar
• Brown A, Hodge W, Kymes SM. Management of neovascular age-related macular degeneration: systematic drug class review and economic evaluation. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health, 2008
   Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98
   PubMed Web of Science ®Google Scholar
• Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008;115:116-26
   PubMed Web of Science ®Google Scholar
• Lang S, Kleijnen J, Noake C. Indirect comparisons of aflibercept with ranibizumab PRN and bevacizumab PRN in wet age-related macular degeneration: a report for Bayer. York, UK: Kleijnen Systematic Review Ltd, 2012
   Google Scholar
• Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-9
   PubMed Web of Science ®Google Scholar
• Brown GC, Brown MM, Brown HC, et al. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology 2007;114:1170-8
   PubMed Web of Science ®Google Scholar
• National Health Insurance Drug Price Standard. Tokyo: Jiho, Inc., 2012
   Google Scholar
• Social Insurance Research Laboratory. Chiyoda-ku, Tokyo: Reimbursement Schedule of Social Insurance. 2012
   Google Scholar
• Yanagi Y, Aihara Y, Fukuda T, et al. [Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese]. Nippon Ganka Gakkai Zasshi 2011;115:825-31
   PubMedGoogle Scholar
• Cabinet Office, Governmet of Japan. Chiyoda-ku, Tokyo 2011 http://www8.cao.go.jp/shougai/data/data_h26/zuhyo55.html. Accessed October 14, 2016
   Google Scholar
• Yanagi Y, Ueta T, Obata R, et al. Utility values in Japanese patients with exudative age-related macular degeneration. Jpn J Ophthalmol 2011;55:35-8
   PubMed Web of Science ®Google Scholar
• Panchmatia HR, Clements KM, Hulbert E, et al. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden. Acta Ophthalmol 2016;94:441-8
   PubMed Web of Science ®Google Scholar
• Czoski-Murray C, Carlton J, Brazier J, et al. Valuing condition-specific health states using simulation contact lenses. Value Health 2009;12:793-9
   PubMed Web of Science ®Google Scholar
• Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc 1999;97:473-511
   PubMedGoogle Scholar
• Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol 2001;85:327-31
   PubMed Web of Science ®Google Scholar
• Sharma S, Brown GC, Brown MM, et al. Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients. Br J Ophthalmol 2002;86:493-6
   PubMed Web of Science ®Google Scholar
• Mitchell P, Annemans L, White R, et al. Cost effectiveness of treatments for wet age-related macular degeneration. Pharmacoeconomics 2011;29:107-31
   PubMed Web of Science ®Google Scholar
• Neubauer AS, Holz FG, Sauer S, et al. Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: model analysis from the perspective of Germany's statutory health insurance system. Clin Ther 2010;32:1343-56
   PubMed Web of Science ®Google Scholar
• Athanasakis K, Fragoulakis V, Tsiantou V, et al. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece. Clin Ther 2012;34:446-56
   PubMed Web of Science ®Google Scholar
• Elshout M, van der Reis MI, Webers CA, et al. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefes Arch Clin Exp Ophthalmol 2014;252:1911-20
   PubMed Web of Science ®Google Scholar
• Kourlaba G, Tzanetakos C, Datseris J, et al. Cost-Effectiveness analysis of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration in Greece. Value Health 2015;18:A421
   Google Scholar
• Iida T, Narimatsu A, Adachi K, et al. Anti-vascular endothelial growth factor outpatient treatment patterns in patients with exudative age-related macular degeneration from a Japanese hospital claims database. JHEOR 2014;2:41-52
   Google Scholar
• McCloud C, Khadka J, Gilhotra JS, et al. Divergence in the lived experience of people with macular degeneration. Optom Vis Sci 2014;91:966-74
   PubMed Web of Science ®Google Scholar